Value202020212022202320242025TTMSelling/general/admin expenses29.61 M57.22 M87.81 M116.81 M111.53 M113.82 M113.82 MResearch & development103.18 M387.09 M311.59 M437.38 M367.56 M409.62 M409.62 MOperating income132.76 M392.46 M338.48 M176.49 M415.57 M383.69 M383.69 MNon-Operating Income, Total118 K21.83 M78.3 M45.32 M38.87 M303.7 M303.7 MInterest expense, net of interest capitalized———————Non-Operating Income, excl. Interest Expenses118 K21.83 M78.3 M45.32 M38.87 M303.7 M303.7 MUnusual income/expense———————Pretax income-29.58 M414.29 M260.18 M131.16 M376.7 M79.99 M623.51 MEquity in earnings——25.5 M25.5 M25.5 M255.15 M—Taxes003.4 M1.37 M39 K00Non-controlling/minority interest———————After tax other income/expense517 K63 K3 0003 0003 000——Net income before discontinued operations194.59 M370.64 M289.09 M132.53 M376.74 M79.99 M79.99 MDiscontinued operations———————Net income194.59 M370.64 M289.09 M132.53 M376.74 M79.99 M79.99 MDilution adjustment2.55 M——————Preferred dividends1.28 M——————Diluted net income available to common stockholders195.87 M370.64 M289.09 M132.53 M376.74 M79.99 M79.99 MBasic earnings per share (Basic EPS)—-5.77-4.13-1.72-4.58-0.81-0.81Diluted earnings per share (Diluted EPS)—-5.77-4.13-1.72-4.58-0.81-0.81Average basic shares outstanding—64.23 M70.02 M77.15 M82.31 M98.91 M391.45 MDiluted shares outstanding—64.23 M70.02 M77.15 M82.31 M98.91 M391.45 MEBITDA———————EBIT———————Cost of revenue———————Other cost of goods sold———————Depreciation & amortization (cash flow)4.74 M7.45 M14.15 M20.01 M21.93 M22.29 M22.29 M
Beam Therapeutics Inc
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.